Investment Pitches

Pitch Summary:
MercadoLibre has taken the best of what other online retailers do, tailored it for its own local markets, and added innovative new services. For instance, in a region with many “unbanked” customers, it built its own payments service and became a leader in digital payments. It then built up a credit business by offering services to customers when banks wouldn’t extend them credit; the retailer has been able to assess borrower risks using both payments and sales data it collects from customers. Another advantage is more physical. In the US, retailers can rely on well-established independent carriers such as FedEx or UPS for deliveries. Not only do those services not exist in large swaths of Latin America, in many places paved roads don’t even exist. MercadoLibre’s solution was to invest billions in its own distribution networks, including physical delivery to the most remote locations. Its own managed logistics network handles 95% of its shipments, and half of those parcels arrive the same or the next day after an order is placed. Much like Amazon’s Prime, it has created its own loyalty program, Meli+, that bundles all these services and offerings to create a compelling user experience. While the competitive landscape is evolving rapidly, MercadoLibre’s deep knowledge of its local customer base, integrated ecosystem, and focus on innovation are its long-term competitive advantages.

BSD Analysis:
MercadoLibre is Latin America’s flagship digital platform — part Amazon, part PayPal, part FedEx — and its ecosystem advantages deepen every year. Mercado Pago has become a financial network of its own, often outgrowing commerce. Logistics investments give MELI the fastest and most reliable delivery in the region, which competitors can’t replicate without burning oceans of capital. The company manages to grow at high double digits while still expanding margins, an almost impossible feat in emerging markets. Macroeconomic volatility is constant, yet MELI’s execution transcends it. Galperin’s leadership and culture of relentless reinvestment remain core differentiators. This is one of the strongest platform flywheels in the world.

Pitch Summary:
We’ve fully exited our position in Globant following the company’s weaker-than-expected Q1 2025 earnings report and disappointing FY25 revenue guidance. While the company has managed to maintain outsized revenue growth relative to its IT services peers for several quarters, recent guidance projecting low single-digit revenue growth for FY25 brings its outlook roughly in line with the peer group. This outcome speaks to the more protracted IT services spending weakness that may continue, and the potentially more discretionary nature of Globant’s business model (which is heavily consulting-based and less reliant on multi-year outsourcing contracts than many larger competitors). Globant may be worth revisiting at a later date, if and when growth reaccelerates. For now, however, we see better risk / reward opportunities elsewhere.

BSD Analysis:
Globant is a high-growth digital transformation specialist whose nearshore, studio-based model provides a superior, non-replicable competitive moat. The core thesis is a conviction bet on the relentless, non-discretionary corporate need to reinvent and become agile using technology, especially in AI. The company's unique structure—a globally cohesive team of over 23,500 creative minds serving 1,100 blue-chip clients—allows it to deliver superior service quality, evidenced by its Net Promoter Score (NPS) of 64. Globant consistently delivers strong financial results, including 59.3% year-over-year revenue growth in 2021. The company is positioned as an indispensable partner for major brands undergoing complex reinvention, justifying its premium valuation.

Pitch Summary:
We initiated a position in IDEXX Labs, a global leader in pet diagnostics, offering in-clinic diagnostics via a razor-and-blades business model—selling instruments and recurring consumables—as well as out-of-clinic reference lab services. We have researched the business for two decades and admired its durable competitive advantages, highly recurring and profitable business model, attractive runway, supported by tailwinds from pet ownership and the “humanization of pets,” and solid execution by its management team. IDEXX employs a successful "surround the customer" strategy by offering diagnostic tests across many modalities, along with imaging and veterinary practice management software. With a dominant market share in pet diagnostic tests, IDEXX continues expanding its addressable market by innovating new testing types and creating additional revenue streams for its veterinary customers. We envision many years of continued innovation and market expansion, with minimal competitive threat. Historically, we questioned IDEXX's persistently high valuation. However, the recent transitory business slowdown—driven by fewer vet clinic visits as COVID-era pets remain relatively young—has made the valuation more attractive. We believe the company’s long-term outlook remains essentially unchanged. As these pets approach 6-7 years of age, their vet care needs will increase, supporting our expectation for sustained double-digit organic revenue growth and mid-to-high teens EPS growth at least in line with the portfolio average. We expect IDEXX to exhibit safety-like characteristics due to its unique competitive position, recurring revenue stream, and loyal shareholder base.

BSD Analysis:
IDEXX is the unassailable, high-growth oligopolist in veterinary diagnostics, whose premium valuation is justified by its superior, non-cyclical growth in the Companion Animal Group (CAG). The core thesis is a conviction bet on the "humanization of pets" and the resulting Diagnostic Advantage—a uniquely competitive "razor and blade" business model where diagnostic analyzers (the "razor") drive long-term demand for high-margin consumables (the "blade"). The financial performance is ruthless: Q3 2025 revenue surged 13% and comparable EPS rose 15%, powered by an impressive 14% organic growth in International CAG Diagnostics recurring revenue. This relentless growth is fueled by a 71% organic expansion in CAG Diagnostics capital instrument revenues in Q3 2025. The stock is a proven compounder, turning a $1,000 investment ten years ago into $10,653.46—a 965.35% gain that crushes the S&P 500's return of 227.69% over the same period. IDEXX is an indispensable, high-quality play on the non-cyclical, long-term structural growth of pet healthcare.

Pitch Summary:
We have reestablished our position in Starbucks, now under the leadership of newly appointed CEO Brian Niccol, formerly of Chipotle. Niccol has articulated a clear, multi-pronged turnaround plan that we view as both practical and achievable. We believe Starbucks’ store operations became overly complex, resulting in over-tasked baristas and a poor customer experience. Having successfully revitalized Chipotle, we view Niccol as the right leader for Starbucks. He has already identified fixes for in-store operations, marketing, and customer service that we believe can potentially result in meaningful impact in the not-too-distant future, provided they are effectively scaled across 17,000 U.S. stores. We believe Starbucks retains an aspirational brand and a loyal customer base. As such, we see solid growth ahead through store productivity, new-store growth, and significant margin expansion. After a few years of mismanagement and a languishing stock, we expect considerable upside for this iconic brand.

BSD Analysis:
Starbucks is a global lifestyle brand oligarch whose future is a leveraged bet on its massive expansion into the Chinese market and its digital ecosystem. The core thesis is a surgical, strategic pivot: Starbucks sold a majority stake in its China retail operations to a Chinese investment firm to accelerate growth into smaller cities and emerging regions. This joint venture, valued at over $13 billion, aims to expand the store footprint to as many as 20,000 locations over time. This localized partnership mirrors McDonald's successful strategy and will help optimize store locations, localize products, and enhance brand competitiveness. This is a high-conviction bet on the long-term, structural growth of the Chinese specialty coffee market, which is forecast to rise to 273.9 billion yuan ($18.6 billion) by 2029.

Pitch Summary:
AI re-emerged as the dominant narrative, driving much of the market’s leadership in the second quarter. Oracle was our top-owned relative contributor, up 56% in the quarter (and 76% since the market bottom on April 9) as the market embraced a meaningful acceleration in growth driven by the Oracle Cloud Infrastructure (OCI) segment. The company appears to be in the early stages of a significant revenue growth increase, fueled partly by its position as a go-to cloud infrastructure provider for training generative AI models. This is only one facet of the investment thesis. Oracle has been successfully migrating enterprise software customers to the cloud as well and is, for the first time, able to finally bring its database clients to the cloud, creating a multi-pronged growth investment thesis. As the air came out of many perceived “AI beneficiaries” amidst elevated tariff-related uncertainty in 1Q, we noted in our previous Quarterly Letter that this had pressured Oracle shares. We took advantage of this weakness by adding to our position in 1Q and again in 2Q, making it one of our largest portfolio weightings.

BSD Analysis:
Oracle is the ruthless, deeply leveraged AI infrastructure pure-play whose stock is trading at a massive discount, creating a volatile but high-conviction entry point. The core thesis is a structural pivot to the Cloud Infrastructure (OCI) business, which management is aggressively positioning to hit $144 billion in revenue by FY2030. This growth is fueled by its massive commitments to AI, including making NVIDIA's most powerful H100 AI processors available on its cloud infrastructure and partnering with companies like Cohere to embed Generative AI capabilities into its applications. OCI offers Generative AI features, including the deployment of Google Gemini models and the beta launch of Agent Hub for creating and deploying AI agents. The critical signal is the 359% surge in its contract backlog (RPO) to $455 billion in Q1 FY2026, which signals durable, long-term commitment from corporate clients. Critics are fixated on the high financial leverage, with the Debt-to-Equity ratio at 436% to 500%—which is much higher than its AI peers—but this is the cost of securing a generational, trillion-dollar market through aggressive CapEx. The company is converting its legacy software dominance into the physical infrastructure required to win the American AI race, a high-stakes bet with no in-between.

Pitch Summary:
NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. These segments are driving both top-line expansion and margin improvement. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. With leading market positions in faster-growing, higher-margin niches, we believe NOF is well-positioned to deliver double-digit growth for years to come, and that the market has yet to fully reflect this structural shift in its valuation. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. NOF operates as an original design manufacturer (ODM) for leading cosmetic brands, including Ryohin Keikaku (popularly known as Muji). The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion, particularly in China. With sustainable double-digit revenue growth and operating margins of 25% or higher, the cosmetics business is well-positioned to support 1–2% annual expansion in group-level margins over the next few years – a key driver of long-term value creation. NOF also has clear visibility into long-term, sustainable growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. Like the cosmetics segment, DDS recently doubled its production capacity to support future demand. The company holds a 60% global market share in polyethylene glycol (PEG) – a key drug additive that enhances stability and prolongs therapeutic effects. In addition, NOF is rapidly scaling its capabilities in lipid nanoparticles, a critical delivery technology for nucleic acid-based therapies (RNA, DNA) and other next-generation treatments. While still in the early stages, the lipid nanoparticle market is projected to grow at a 40% annual rate, positioning NOF to benefit from secular growth well into the 2030s. A final growth catalyst lies in NOF’s explosives division, which represents approximately 10% of sales and holds a 100% market share in Japan for rocket propellants used by the Self-Defense Forces (SDF). While the company provides limited disclosure on this segment, it recently announced a doubling of capacity to meet rising demand. However, with captive customers like IHI ramping up missile and rocket production by several multiples, even this expansion is unlikely to fully meet growing needs – suggesting continued upside and strategic importance for this niche, high-barrier business. NOF is also making encouraging progress on corporate governance. While the introduction of a formal Investor Relations function and explicit shareholder return policies may seem like modest steps, they represent meaningful improvements for the company. With only two analysts currently covering what is otherwise a well-established “mid-cap” company, we believe there is still significant discovery and re-rating potential as governance standards improve and investor visibility increases.

BSD Analysis:
NOF is riding twin secular trends: the biologics explosion and the demand for specialty materials in semiconductors and coatings. Its diversified portfolio makes it resilient, while its deep pharma ties give it pricing power. Investors still treat it like a mundane chemicals company — but NOF is a global advanced-materials supplier with real growth.

Pitch Summary:
Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. The company is widely recognized for its fast, reliable technology infrastructure. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. The court found Google had engaged in anti-competitive practices, and a follow-up hearing this September could result in structural changes that benefit independent ad tech providers. CTV now represents approximately 50% of Magnite’s revenue, with the segment expected to grow at a 15% CAGR over the medium term. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner, positioning it to benefit as Netflix targets $9 billion in ad revenue by 2030. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. Despite its relatively small share, open web ads still account for approximately 40% of Magnite’s revenue. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. To illustrate the upside: each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue (with about 90% incremental margin) – equivalent to roughly half of Magnite’s 2024 EBITDA. At current valuations – 15x forward EBITDA for Magnite – we believe this embedded optionality is not yet priced in, and the stocks could offer 50–100% upside from current levels.

BSD Analysis:
Magnite is the DSP alternative that’s benefiting from fragmentation of the streaming ecosystem. As every platform launches or expands ad tiers, supply-side partners become more important, and Magnite is already embedded. The company has cleaned up its cost structure, boosted ad quality, and strengthened its pipeline in CTV. This is a levered bet on the future of programmatic TV — and it’s still early.

Pitch Summary:
NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. These segments are driving both top-line expansion and margin improvement. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. With leading market positions in faster-growing, higher-margin niches, we believe NOF is well-positioned to deliver double-digit growth for years to come, and that the market has yet to fully reflect this structural shift in its valuation. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. NOF operates as an original design manufacturer (ODM) for leading cosmetic brands, including Ryohin Keikaku (popularly known as Muji). The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion, particularly in China. With sustainable double-digit revenue growth and operating margins of 25% or higher, the cosmetics business is well-positioned to support 1–2% annual expansion in group-level margins over the next few years – a key driver of long-term value creation. NOF also has clear visibility into long-term, sustainable growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. Like the cosmetics segment, DDS recently doubled its production capacity to support future demand. The company holds a 60% global market share in polyethylene glycol (PEG) – a key drug additive that enhances stability and prolongs therapeutic effects. In addition, NOF is rapidly scaling its capabilities in lipid nanoparticles, a critical delivery technology for nucleic acid-based therapies (RNA, DNA) and other next-generation treatments. While still in the early stages, the lipid nanoparticle market is projected to grow at a 40% annual rate, positioning NOF to benefit from secular growth well into the 2030s. A final growth catalyst lies in NOF’s explosives division, which represents approximately 10% of sales and holds a 100% market share in Japan for rocket propellants used by the Self-Defense Forces (SDF). While the company provides limited disclosure on this segment, it recently announced a doubling of capacity to meet rising demand. However, with captive customers like IHI ramping up missile and rocket production by several multiples, even this expansion is unlikely to fully meet growing needs – suggesting continued upside and strategic importance for this niche, high-barrier business. NOF is also making encouraging progress on corporate governance. While the introduction of a formal Investor Relations function and explicit shareholder return policies may seem like modest steps, they represent meaningful improvements for the company. With only two analysts currently covering what is otherwise a well-established “mid-cap” company, we believe there is still significant discovery and re-rating potential as governance standards improve and investor visibility increases.

BSD Analysis:
NOF’s dominance in high-purity chemicals and biologic drug components makes it irreplaceable to pharma giants who require reliability and consistency. Demand for advanced controlled-release and lipid-based drug delivery keeps climbing, and NOF owns that niche. With expanding semiconductor-materials demand and elite margins, NOF is one of Japan’s quietest, highest-quality industrial-science hybrids.

Pitch Summary:
Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. The company is widely recognized for its fast, reliable technology infrastructure. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. The court found Google had engaged in anti-competitive practices, and a follow-up hearing this September could result in structural changes that benefit independent ad tech providers. CTV now represents approximately 50% of Magnite’s revenue, with the segment expected to grow at a 15% CAGR over the medium term. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner, positioning it to benefit as Netflix targets $9 billion in ad revenue by 2030. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. Despite its relatively small share, open web ads still account for approximately 40% of Magnite’s revenue. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. To illustrate the upside: each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue (with about 90% incremental margin) – equivalent to roughly half of Magnite’s 2024 EBITDA. At current valuations – 15x forward EBITDA for Magnite – we believe this embedded optionality is not yet priced in, and the stock could offer 50–100% upside from current levels.

BSD Analysis:
Magnite’s real competitive advantage isn’t scale — it’s neutrality. As streaming platforms shift to ad-supported tiers, they need partners they can trust with auction dynamics and transparency. Magnite fills that role perfectly. With device-level CTV growth accelerating, Magnite is positioned directly in front of the next wave of premium programmatic monetization. The market still prices it like a flaky ad-tech small cap — but the runway is long and the model is getting sturdier.

Pitch Summary:
NOF Corporation (Japan – $4.6 billion market cap). NOF is a Japanese company with a compelling investment profile: a stable, cash-generative core business in functional chemicals, supported by high-growth segments in cosmetics and pharmaceuticals. Despite this favorable mix, the company continues to trade like a basic chemicals business at just 17x earnings. In the near term, cosmetic surfactants – which account for approximately 20% of NOF’s sales and 25% of profits – are poised to drive meaningful upside, following a recent doubling of production capacity. The cosmetics segment grew 36% last year, fueled by Ryohin’s success and continued store expansion. NOF also has clear visibility into long-term growth through its Pharmaceutical and Drug Delivery Systems (DDS) platform, which now accounts for about 20% of sales and 35% of profits. The company holds a 60% global market share in polyethylene glycol (PEG) and is scaling rapidly in lipid nanoparticles for next-generation therapies. A final growth catalyst lies in NOF’s explosives division, which holds a 100% domestic market share in rocket propellants for the Self-Defense Forces, with capacity recently doubled to meet rising demand. Management is also making progress on governance and investor communication, increasing discovery and re-rating potential.

BSD Analysis:
NOF is the Japanese specialty-chemicals giant powering everything from biologics manufacturing to electronic materials, surfactants, and advanced polymers. Its PEGylation and lipid delivery technologies make it a hidden enabler of next-gen therapies and mRNA drugs. Margins are steady, R&D depth is underrated, and global expansion into pharma ingredients gives NOF multi-year growth visibility. This is a quiet compounder the market chronically underprices.

Pitch Summary:
Magnite, Inc. (U.S. – $3 billion market cap). Magnite is one of the largest independent sell-side platforms (SSPs) – effectively serving as enterprise software for digital publishers, including websites and connected TV channels. Its platform enables publishers to manage ad serving, optimize yield, and target audiences more effectively by connecting their ad inventory to a broad network of demand partners. In return, SSPs earn a percentage of ad spend flowing through their platforms. Magnite benefits from deep integrations with publishers and demand-side platforms, creating high switching costs and a durable competitive moat. Two major trends are reshaping the digital advertising landscape. First, ad budgets continue to shift from traditional linear TV to Connected TV (CTV) as platforms like Netflix and others expand their ad-supported offerings. Second, a recent antitrust ruling against Google may significantly alter the dynamics of the open web advertising market – specifically for video and display ads on browser-based websites. CTV now represents approximately 50% of Magnite’s revenue. The company is well-positioned to outpace this growth thanks to their scale, deep publisher relationships, and strong technology platforms. In mid-2024, Magnite was named Netflix’s exclusive ad tech partner. In the open web advertising market, Google maintains a dominant 60% share, compared to 7% for Magnite. A meaningful shift in market share following the recent antitrust ruling could serve as a powerful catalyst, with potential double-digit revenue growth beginning in 2026. Each 1% shift in market share away from Google would translate into an estimated $50–75 million in high-margin revenue.

BSD Analysis:
Magnite is the independent ad-tech platform riding the shift toward CTV and premium programmatic — a space where advertisers want alternatives to walled gardens. Revenue is stabilizing, CTV spend is rising, and Magnite’s supply-path optimization capabilities give it real strategic relevance. The balance sheet is improving, margins are firming, and the worst of the post-pandemic ad slump appears behind it. Magnite remains one of the few scaled independents positioned to benefit from the secular growth of programmatic.

Pitch Summary:
Ziff Davis (ZD) is a diversified digital media and internet services company trading at just 4× EBITA and under 6× earnings despite strong free cash flow generation and disciplined capital allocation. The business spans five verticals—Technology & Shopping, Gaming & Entertainment, Health & Wellness, Connectivity, and Cybersecurity & Martech—supported by recurring B2B and subscription revenue streams. With $1.4B in 2024 revenue, $494M EBITDA, and $374M EBIT, the company trades at an EV of ~$1.6B, implying a 10–12% FCF yield and substantial margin of safety. Management has repurchased 10% of shares at ~$50/share, maintains low leverage, and has a clear 20% ROIC hurdle for acquisitions.

BSD Analysis:
Ziff Davis is a misunderstood collection of durable niche digital brands with recurring cash flow, disciplined management, and significant buyback support. Despite investor skepticism toward legacy digital publishers and AI’s impact on web traffic, ZD’s diversified assets (e.g., PCMag, IGN, Speedtest, Everyday Health, Vipre) benefit from unique data and subscription-based models, reducing exposure to search-driven traffic. CEO Vivek Shah has consistently executed value-accretive M&A and returned cash to shareholders, producing steady EPS growth. The stock’s extreme valuation discount (4× EV/EBITA, 2.8× EBITDA) is unjustified given its 25–35% margins, strong balance sheet, and capital discipline. Upside could be realized through ongoing buybacks, sum-of-the-parts recognition, or a strategic sale.

Pitch Summary:
Sensient Technologies (SXT) is the global leader in natural food colors and stands to be a major beneficiary of the accelerating regulatory shift away from synthetic dyes in the U.S., catalyzed by the RFK Jr. administration’s “Make America Healthy Again” (MAHA) initiative and pending bans such as Red Dye No. 3 by 2027. With roughly half of its EBIT derived from colors—60% already natural—Sensient is uniquely positioned to capture this transformation as demand for natural ingredients surges. Natural colors command 2x pricing and 10x the required volume compared to synthetics, creating a powerful revenue uplift opportunity. As the U.S. lags Europe in natural adoption (33% vs. 80%), Sensient’s leadership in this space could drive outsized growth in the coming years.

BSD Analysis:
Sensient’s dual capability in synthetic and natural colors—paired with its complementary flavors and extracts business—provides a defensible moat in the global ingredients landscape. Limited analyst coverage (only two long-term analysts globally) and the predominance of European-listed peers have kept SXT off the radar of major institutional investors, creating an underfollowed U.S. mid-cap opportunity. With earnings projected to rise from ~$3.00 to $5.78 by 2026 and regulatory tailwinds accelerating U.S. reformulations, Sensient should deliver both organic growth and potential M&A interest from larger European ingredient consolidators. Applying a 25× multiple to 2026 EPS yields a $144.5 target. The transition to natural colorants could represent the company’s most meaningful growth phase in decades.

Pitch Summary:
Oxford Biomedica (OXB) is a leading viral vector CDMO with entrenched partnerships across cell and gene therapy (CGT) programs, including Novartis’s Kymriah and likely Legend/J&J’s CARVYKTI. The company is transitioning from R&D-heavy biotech to a pure-play contract manufacturer with >35% revenue CAGR through 2026, targeting 20% EBITDA margins as commercial volumes ramp. With 48 programs across 35+ clients and a growing share of high-value AAV work, OXB stands to benefit from the accelerating adoption of CGT and the industry’s shift toward outsourced vector manufacturing. Despite marquee clients and top-tier science, shares trade at just ~2.3× 2025 sales and 11× 2026E EBITDA—less than half the multiples of peers and recent CDMO takeouts.

BSD Analysis:
Oxford Biomedica has repositioned itself as a focused, high-growth CDMO at the heart of the viral vector supply chain for cell and gene therapies. With proven lentiviral expertise, expanding AAV capabilities, and a strong client roster including Novartis, J&J/Legend, Arcellx, and Kyverna, OXB is now benefiting from the commercial ramp of multiple late-stage programs. Its scalable platform, demonstrated 500L lentiviral production at 90% full capsids, and established regulatory track record provide high barriers to entry in an industry constrained by capacity and know-how. Near-term catalysts—positive EBITDA in 2025, potential Serum Institute revenue, and rising demand for commercial manufacturing—should drive multiple expansion. With Novo Holdings and Merieux as strategic shareholders, OXB is a prime M&A candidate in a consolidating CDMO landscape.

Pitch Summary:
Champions Oncology (CSBR) is a pre-clinical CRO focused on oncology drug testing and data solutions, trading at just ~12× forward earnings with a $106M market cap and net cash. Its deep bank of 1,400 patient-derived xenograft (PDX) tumor models—predominantly U.S.-derived and fully characterized—gives it a defensible moat against peers like Crown Bio and Charles River. The company’s core in-vivo/ex-vivo testing business is stable (~5–6% growth), while its emerging data licensing segment could transform economics. A recent $8M data deal with a top-five pharma validated this high-margin opportunity, and management expects multiple similar agreements that could double EBITDA within three years. With aligned insider ownership (~70%), strong FCF, and a growing AI-driven demand for biological datasets, CSBR offers 2–3× upside over the next few years with limited downside.

BSD Analysis:
Champions Oncology combines a high-barrier PDX-based CRO model with a unique proprietary oncology dataset poised to monetize through AI-driven data licensing. The core in-vivo and ex-vivo business generates recurring high-margin revenue, while recent data deals signal a scalable, asset-light growth engine. With strong insider alignment, 17%+ revenue CAGR, and potential EBITDA expansion from ~$8M to $30M through new data contracts, CSBR represents a compelling small-cap growth opportunity. Upside catalysts include additional pharma data partnerships and improved investor communication.

Pitch Summary:
Long idea: Europe’s dominant low-cost gym chain (≈1,600 clubs; ~54% in France) is emerging from post-COVID cohort drag with unit economics trending back to 2016–2019 vintages. The crux is France: moving clubs to 24/7 access plus expected relaxation of “staffed hours” rules could flip a 2025 €35m temporary staffing headwind into savings and unlock incremental membership growth. Author models ~€455–500m 2026 adj. EBITDA (weighted ~€477m), vs consensus ~€404m, with 80% probability on the high end if most French clubs run 24/7 staff-light. Each 24/7 conversion adds members at very high incremental margins (~80%), and insourcing/going staffless removes much of the €35m opex. Beyond France, the model benefits from maturation tailwinds as a larger share of the estate becomes “mature,” plus continued clustering, lowest-cost procurement, and standardized build costs (~€1.3m per club, 3–4yr payback). Benelux showcases steady-state margins (≈47% EBITDA), while Germany/Spain are long runways. At ~€2.6bn TEV the stock screens at ~5.3x the author’s 2026 EBITDA and 7.5x 2025, a trough vs pre-COVID 9–13x. On €529m 2027E EBITDA, 10x implies ~€65/share (>2.5× upside). With sentiment reset after years of misses, a “beat and raise” phase could catalyze multiple expansion back toward growth comps.

BSD Analysis:
Non-consensus because the upside hinges on France-specific operational/legal changes that the market discounts after a multi-year hangover. The bet is that 24/7 access drives member adds while staffing rules ease, turning a 2025 opex drag into 2026+ EBITDA. Risks: French labor reform timing, slower adoption of 24/7 at the “next 500” clubs, and any renewed cohort underperformance; mitigants include visible maturation mix shift, structural cost edge (procurement, labor-light model), and clustering that deters entrants. If consensus lifts toward €455–500m EBITDA, a rerate toward 9–10× is plausible.

Pitch Summary:
Long idea: OXB is a UK-listed viral vector CDMO with leading positions in lentiviral manufacturing and growing AAV capabilities, supplying top-tier clients in the cell & gene therapy space. Originally a biotech, it pivoted fully to contract development and manufacturing in 2022, leveraging its work with Novartis’s Kymriah and AstraZeneca’s Covid vaccine to build credibility. The company is likely manufacturing vectors for J&J/Legend’s CARVYKTI via Novartis, which could become a very large program as supply doubles in 2025. Management guides to EBITDA profitability in 2025 and 20% margins by 2026, with revenue growing >35% CAGR from 2023–26, outpacing the ~20% CGT market growth. The pipeline spans 48 programs, 6 of which are late-stage or commercial, with a disclosed pipeline value of ~$570M. Despite strong fundamentals, OXB trades cheaply at ~2.3× 2025 sales and ~11× 2026E EBITDA, with little coverage due to its UK listing, low liquidity, lack of profitability to date, and investor wariness of biotech. The CGT market is gaining share of FDA approvals (10% in 2023 vs. 4% in 2020), and viral vectors remain the dominant delivery modality despite emerging competition from LNPs. Strategic backers (Novo Holdings, Merieux Alliance) and potential takeout comps (Thermo Fisher, Catalent) suggest OXB could attract M&A interest. Upside case is 2–3× by 2027 on execution of growth and margin ramp, with catalysts including commercial revenue from CARVYKTI, Serum Institute agreements, and broader CGT adoption.

BSD Analysis:
Non-consensus because OXB is seen as a Covid “loser” and still unprofitable, but its pivot to CDMO with marquee clients gives it stealth quality. The CARVYKTI exposure could be transformational, yet is not well disclosed to investors. Risks include competition from LNP delivery and CGT cost concerns, but the viral vector moat looks durable mid-term. Valuation is compelling versus history and peers (M&A at 12× sales, vs. OXB 2.3×). This has both growth and M&A optionality, making it a classic overlooked UK small-cap with global relevance.

Pitch Summary:
Long idea on a niche oncology pre-clinical CRO built around a uniquely deep, US-sourced, highly annotated PDX tumor bank that underpins four revenue streams: in-vivo studies (~75% of rev), ex-vivo organoids (~9% and growing), other lab services, and a nascent but potentially transformative data-licensing business. Core in-vivo is a steady mid-single-digit grower; ex-vivo and lab services should outgrow as models move “off-the-shelf.” The new data business just landed an ~$8M top-5 pharma license (with a further $3.5M option), extremely high margin and repeatable as Champions enriches the dataset; management thinks it could rival the core within ~3 years. Moat stems from scale/recency of US patient tumors and “deep not long” multi-omic, phenotypic, and pharmacologic annotations—hard and time-consuming to replicate. Industry tailwinds (biopharma outsourcing, oncology R&D, AI-driven demand for biological datasets) support double-digit growth pockets. Management/board are heavily aligned (insiders/affiliates own >40%), capital discipline is decent, and balance sheet has net cash (~$3M). Base case: core + services grow ~6–15% with data scaling, yielding ~$18M 2027 EBITDA; bull: multiple data licenses (~$24M) drives ~$31.6M EBITDA. On trough valuation (~12x next-year EPS / low-teens EV/EBITDA for pre-clinical CROs), shares look mispriced at a ~$106M cap. Author frames 130–300% upside depending on data-deal cadence.

BSD Analysis:
Non-consensus because the market anchors on a tiny cap, thin IR, and past conversion of revenue to FCF, while underpricing the step-function from licensing ultra-high-value datasets (and optional royalties/milestones) on top of a durable PDX services base. Key risks: data deals slip or fail; CRO budgets tighten; customer concentration; governance/float (insiders & 3 holders >70%). Mitigants: recent top-5 pharma win validates willingness to pay; moat from US-derived, deeply annotated models; ex-vivo growth hedges any long-run animal-testing shift; net-cash balance sheet. If additional licenses land, a rerate toward mid-teens EV/EBITDA (peer deal comps 11–16×) is plausible.

Pitch Summary:
Long idea: Ziff Davis is a digital media and data conglomerate built through ~90 acquisitions, spanning technology, gaming, health, connectivity, and cybersecurity assets. The portfolio includes brands like PCMag, IGN, Everyday Health, Speedtest, and Vipre. While critics view ZD as a collection of second-tier assets vulnerable to AI disruption in content, the company emphasizes recurring revenues (≈40% from subscriptions/data) and smart capital allocation. Management targets 20% cash-on-cash returns on M&A and historically achieved 16–17% EBITDA on invested capital. At ~$31 per share, the stock trades at ~2.8× EBITDA, ~3.9× EBITA, and ~5× EPS — unusually cheap for a debt-light company still generating cash. Organic growth remains slightly negative (-3% in Q1’25), but trends are improving, and management continues to repurchase stock aggressively (10% of shares in the past year at ~$50/share). Insiders, including the CEO, have also bought stock recently, signaling confidence. The business model mixes stable B2B subscription/data services with more volatile media assets, providing a base of recurring cash flow. Given its low valuation, ongoing buybacks, and management’s focus on ROIC, ZD offers asymmetric upside either through self-help, sum-of-the-parts recognition, or eventual acquisition.

BSD Analysis:
Non-consensus because many investors dismiss ZD as a declining digital media roll-up, but the stock trades at distressed multiples despite strong cash generation and conservative leverage. The hidden value lies in its recurring/data businesses and disciplined capital allocation, which differentiate it from generic ad-driven publishers. With sustained buybacks and insider alignment, downside is limited, while upside could be realized through valuation normalization or a takeout.

Pitch Summary:
Long idea: Sensient is a U.S.-based specialty ingredients company, best known for its leadership in natural food colors. About half of EBIT comes from colors (60% natural, 40% synthetic), with the rest from flavors, extracts, and its China business. Regulatory changes under RFK Jr.’s administration, including bans on synthetic dyes (e.g., Red Dye No. 3 by 2027), are accelerating demand for natural alternatives. Sensient stands to benefit disproportionately because natural colors require ~10x the volume of synthetics and sell at ~2× the price, creating a powerful revenue uplift. Global adoption is uneven (EU ~80% natural vs. U.S. ~33%), giving the company a long runway for U.S. catch-up. Management sees this as one of the biggest growth opportunities in its history, and consensus estimates ($4.52 EPS 2025E, $5.78 2026E) may prove conservative. Valuation at ~19× 2026E earnings looks reasonable, with a 25× multiple on $5.78 yielding a ~$145 stock, +32% upside. The company is underfollowed, with limited analyst coverage (mostly European ingredient specialists), making it overlooked by many U.S. investors. In addition, consolidation in the global ingredients industry makes SXT a credible M&A candidate for larger EU players.

BSD Analysis:
Non-consensus because the Street underestimates how fast regulatory bans and consumer sentiment will accelerate the shift to natural colors in the U.S., where penetration is still low. The volume and pricing uplift dynamics are not widely appreciated, and SXT is uniquely positioned as the #1 player. With underfollowed U.S. coverage, valuation could rerate closer to EU peers, or the company could be taken out. Risks include execution in reformulations, timing of bans, and broader ingredient inflation, but the asymmetric setup offers attractive upside.